Distribution of pomalidomide into semen of healthy male subjects after multiple doses

Yan Li,1 Xiaomin Wang,2 Liangang Liu,3 Josephine Reyes,1 Maria Palmisano,1 Simon Zhou1 1Translational Development and Clinical Pharmacology, Celgene Corporation, Summit, NJ, USA; 2Non-Clinical Development, Celgene Corporation, Summit, NJ, USA; 3Biometrics and Data Operations, Celgene Corporation, Su...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Li Y, Wang X, Liu L, Reyes J, Palmisano M, Zhou S
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	pomalidomide distribution semen teratogen kinetics Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/ed6999723c13435ea542dd8840d7037a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ed6999723c13435ea542dd8840d7037a
record_format	dspace
spelling	oai:doaj.org-article:ed6999723c13435ea542dd8840d7037a2021-12-02T11:22:16ZDistribution of pomalidomide into semen of healthy male subjects after multiple doses1179-1438https://doaj.org/article/ed6999723c13435ea542dd8840d7037a2018-05-01T00:00:00Zhttps://www.dovepress.com/distribution-of-pomalidomide-into-semen-of-healthy-male-subjects-after-peer-reviewed-article-CPAAhttps://doaj.org/toc/1179-1438Yan Li,1 Xiaomin Wang,2 Liangang Liu,3 Josephine Reyes,1 Maria Palmisano,1 Simon Zhou1 1Translational Development and Clinical Pharmacology, Celgene Corporation, Summit, NJ, USA; 2Non-Clinical Development, Celgene Corporation, Summit, NJ, USA; 3Biometrics and Data Operations, Celgene Corporation, Summit, NJ, USA Objective: To assess whether pomalidomide can distribute into human semen and its duration in human semen. Method: A phase 1, randomized, double-blind, placebo-controlled study (CC-4047-CP-006) was conducted to evaluate the safety, tolerability, and pharmacokinetics of pomalidomide (CC-4047) following multiple daily doses in healthy male subjects. Semen samples were collected on Day −1 and 4 hours after dosing on Day 4 to quantify the pomalidomide concentrations in ejaculate after multiple oral doses of pomalidomide. Result: Our study showed that pomalidomide was present in male subjects’ semen samples, and the average amount of pomalidomide in a single ejaculate 4 hours after dosing was less than 0.0022% of the daily 2 mg dose. There was a good correlation between the semen concentrations and the plasma concentrations, suggesting that the plasma concentration may be the main driving force for the distribution of pomalidomide into the seminal reservoirs. Simulation results suggest that pomalidomide was undetectable in semen 48 hours after stopping dosing. Conclusion: Based on the results from this study, the pomalidomide prescribing information approved by the US Food and Drug Administration includes a statement that “pomalidomide is present in the semen of patients receiving the drug. Therefore, males must always use a latex or synthetic condom during any sexual contact with females of reproductive potential while taking POMALYST and for up to 4 weeks after discontinuing POMALYST, even if they have undergone a successful vasectomy. Male patients taking POMALYST must not donate sperm.” Keywords: pomalidomide, distribution, semen, teratogen, kineticsLi YWang XLiu LReyes JPalmisano MZhou SDove Medical PressarticlepomalidomidedistributionsementeratogenkineticsTherapeutics. PharmacologyRM1-950ENClinical Pharmacology: Advances and Applications, Vol Volume 10, Pp 53-62 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	pomalidomide distribution semen teratogen kinetics Therapeutics. Pharmacology RM1-950
spellingShingle	pomalidomide distribution semen teratogen kinetics Therapeutics. Pharmacology RM1-950 Li Y Wang X Liu L Reyes J Palmisano M Zhou S Distribution of pomalidomide into semen of healthy male subjects after multiple doses
description	Yan Li,1 Xiaomin Wang,2 Liangang Liu,3 Josephine Reyes,1 Maria Palmisano,1 Simon Zhou1 1Translational Development and Clinical Pharmacology, Celgene Corporation, Summit, NJ, USA; 2Non-Clinical Development, Celgene Corporation, Summit, NJ, USA; 3Biometrics and Data Operations, Celgene Corporation, Summit, NJ, USA Objective: To assess whether pomalidomide can distribute into human semen and its duration in human semen. Method: A phase 1, randomized, double-blind, placebo-controlled study (CC-4047-CP-006) was conducted to evaluate the safety, tolerability, and pharmacokinetics of pomalidomide (CC-4047) following multiple daily doses in healthy male subjects. Semen samples were collected on Day −1 and 4 hours after dosing on Day 4 to quantify the pomalidomide concentrations in ejaculate after multiple oral doses of pomalidomide. Result: Our study showed that pomalidomide was present in male subjects’ semen samples, and the average amount of pomalidomide in a single ejaculate 4 hours after dosing was less than 0.0022% of the daily 2 mg dose. There was a good correlation between the semen concentrations and the plasma concentrations, suggesting that the plasma concentration may be the main driving force for the distribution of pomalidomide into the seminal reservoirs. Simulation results suggest that pomalidomide was undetectable in semen 48 hours after stopping dosing. Conclusion: Based on the results from this study, the pomalidomide prescribing information approved by the US Food and Drug Administration includes a statement that “pomalidomide is present in the semen of patients receiving the drug. Therefore, males must always use a latex or synthetic condom during any sexual contact with females of reproductive potential while taking POMALYST and for up to 4 weeks after discontinuing POMALYST, even if they have undergone a successful vasectomy. Male patients taking POMALYST must not donate sperm.” Keywords: pomalidomide, distribution, semen, teratogen, kinetics
format	article
author	Li Y Wang X Liu L Reyes J Palmisano M Zhou S
author_facet	Li Y Wang X Liu L Reyes J Palmisano M Zhou S
author_sort	Li Y
title	Distribution of pomalidomide into semen of healthy male subjects after multiple doses
title_short	Distribution of pomalidomide into semen of healthy male subjects after multiple doses
title_full	Distribution of pomalidomide into semen of healthy male subjects after multiple doses
title_fullStr	Distribution of pomalidomide into semen of healthy male subjects after multiple doses
title_full_unstemmed	Distribution of pomalidomide into semen of healthy male subjects after multiple doses
title_sort	distribution of pomalidomide into semen of healthy male subjects after multiple doses
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/ed6999723c13435ea542dd8840d7037a
work_keys_str_mv	AT liy distributionofpomalidomideintosemenofhealthymalesubjectsaftermultipledoses AT wangx distributionofpomalidomideintosemenofhealthymalesubjectsaftermultipledoses AT liul distributionofpomalidomideintosemenofhealthymalesubjectsaftermultipledoses AT reyesj distributionofpomalidomideintosemenofhealthymalesubjectsaftermultipledoses AT palmisanom distributionofpomalidomideintosemenofhealthymalesubjectsaftermultipledoses AT zhous distributionofpomalidomideintosemenofhealthymalesubjectsaftermultipledoses
_version_	1718395971726999552

Distribution of pomalidomide into semen of healthy male subjects after multiple doses

Ejemplares similares